View Older Stories View More Recent Stories
-
Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts
-
Ainos (AIMD) to Initiate Taiwan Clinical Study for VELDONA
-
Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
-
Ainos (AIMD) Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention
-
Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention
-
Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference
-
Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter
-
Ainos (AIMD) Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety
-
Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety
-
Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024
-
Ainos (AIMD) Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
-
Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
-
Ainos Concludes Growth Financing From Lind Partners
-
Ainos Reports Second Quarter 2024 Financial Results
-
Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug
-
Ainos (AIMD) Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA
-
Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA
